Pexidartinib not checked
Daiichi Sankyo · PLX3397
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- How it’s given
- “400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)”In the company’s words, NCT04488822 on ClinicalTrials.gov
- Tested for
- Tenosynovial Giant Cell Tumor
- Main trialPhase 3
- “This study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.”In the company’s words, NCT04488822 on ClinicalTrials.gov
- Other names
- TURALIO · PLX3397
Other drugs for Tenosynovial Giant Cell Tumor
- VimseltinibDeciphera Pharmaceuticals, LLC · Phase 3
- EmactuzumabSynOx Therapeutics Limited · Phase 3
- PimicotinibMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 27 Oct 2021 | A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT | |
| Phase 4Completed | 7 Jul 2023 | Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib | |
| Phase 3Completed | 27 Mar 2017 | Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) | |
| Phase 2Completed | 20 Mar 2023 | A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan | |
| Phase 1Completed | 13 Jun 2017 | Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors | |
| Phase 1Completed | 31 Jan 2018 | Safety Study of PLX108-01 in Patients With Solid Tumors | |
| Phase 1Completed | 26 Sep 2018 | Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026